Avantor Inc. (AVTR) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, AVTR scores 59 out of 100, equating to a C- grade and the verdict "Roarable Hold — Cautious Neutral." The five pillars are:

• Fundamental Cash Engine (10/20): Per the RQD rating, this pillar reflects ROIC of -2.1% and an FCF yield of 4.38%. Negative ROIC means the business is not currently earning returns above its capital base, a meaningful drag on this pillar. The positive FCF yield indicates the company still generates cash relative to its market value, which partially offsets the weak return profile.
• Whale 13F Flow (18/20): This is the strongest pillar, described per the RQD rating as reflecting institutional accumulation and options positioning. For a prospective investor, this suggests larger holders have been building or maintaining positions, a potential support factor. The underlying 13F holder detail itself is not provided in the source data.
• Insider Conviction (11/20): Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow at a moderate level. Mid-range insider signal suggests neither strong insider buying conviction nor significant selling pressure.
• Macro Regime Fit (11/20): Per the RQD rating, beta is 1.01, meaning the stock has moved roughly in line with the market. Sector sensitivity is noted but not further quantified in the source data. Investors should expect returns to track broader market and sector conditions.
• Forensic Balance Sheet (9/20): Per the RQD rating, Altman Z is 1.88, Piotroski F is 5/9, and Debt/Equity is 0.7. A Z-score in this range is commonly viewed as a financial-distress caution zone; the Piotroski score is moderate. This is the second-weakest pillar and a central risk consideration.

Investor implications: The rating points to a mixed picture. Upside drivers include institutional positioning and the positive FCF yield. Valuation tradeoffs are significant: the forward P/E of 31 is elevated relative to the negative trailing EPS of -0.78, and P/E (TTM) is not available in source data, so the valuation rests heavily on expectations of earnings recovery. The balance sheet and negative returns on capital are the principal headwinds. The verdict of "Cautious Neutral" reflects this balance rather than a directional call.

Avantor Inc. is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry, per the profile. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data. Specifics on product lines, customer segments, and revenue mix are not available in source data.

Per the SEC financials, revenue declined from $6967.2M (FY 2023) to $6552.2M (FY 2025), and FY 2025 moved to an operating loss of $-246.2M and net loss of $-530.2M after positive results in FY 2024. Operating margin is -3.8% and net margin is -8.1% per market data. ROIC is -2.1%. Per the RQD rating, the Altman Z-Score is 1.88 and the Piotroski F-Score is 5/9. Debt rose from $1956.4M (FY 2023) to $3915.5M (FY 2025), and Debt/Equity is 0.7 per the RQD rating.

• Market wire (YELLOW): "Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?" — Yahoo Finance.
• Catalyst (GREEN): "Avantor (AVTR) is Regaining Market Confidence" — Yahoo Finance.
• Market wire (YELLOW): "Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28" — Seeking Alpha.
• Catalyst (GREEN): "Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says" — GuruFocus.
• Risk watch (RED): "Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall" — Simply Wall St.
• Risk watch (RED): "Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution" — Yahoo Finance.

Per the news feed, catalyst items are mixed: two positive catalysts, two market-wire items, and two risk-watch items referencing the Q3 earnings reaction and the five-year decline. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, there are no butterfly links, and there are no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data. The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.

• What drove the swing from FY 2024 net income of $711.5M to FY 2025 net loss of $-530.2M, and is it recurring or one-time?
• What is the trailing P/E and EV/EBITDA, given both are unavailable in source data while forward P/E is 31?
• How much of the $3915.5M debt load is near-term maturity, and what is the refinancing profile?
• What are the drivers of the 13F accumulation signal, and which institutions are involved?
• What is the FY 2025 EPS, which is reported as N/A?